U.S. Food and Drug Administration Approves Cangene's Anti-Hepatitis B Product, Winnipeg Company Says
January 31, 2006
On Monday, Cangene Corp. said the Food and Drug Administration has approved its HepaGam B treatment for hepatitis B virus (HBV) for sale in the United States. The drug has been approved for treatment of acute exposure to blood containing HBV surface antigen, perinatal exposure of infants born to infected mothers, and sexual and household exposure to infected persons. Winnipeg-based Cangene expects HepaGam B will be launched within a few months and be distributed by Apotex Corp.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.